A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to (177)Lutetium-DOTA-octreotate radionuclide therapy

Peptide receptor radionuclide therapy (PRRT) using (177)Lutetium-DOTA-octreotate (LuTate) for neuroendocrine tumours (NET) is now an approved treatment available in many countries, though primary or secondary resistance continue to limit its effectiveness or durability. We hypothesised that a genome...

Descripción completa

Detalles Bibliográficos
Autores principales: Waldeck, Kelly, Van Zuylekom, Jessica, Cullinane, Carleen, Gulati, Twishi, Simpson, Kaylene J., Tothill, Richard W., Blyth, Benjamin, Hicks, Rodney J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526672/
https://www.ncbi.nlm.nih.gov/pubmed/37771787
http://dx.doi.org/10.7150/thno.84628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526672/
https://www.ncbi.nlm.nih.gov/pubmed/37771787
http://dx.doi.org/10.7150/thno.84628

Ejemplares similares